11th Edition of Clinical Trials on Alzheimer Disea
Post# of 30028
(Total Views: 440)
Posted On: 11/05/2018 6:58:10 PM
11th Edition of Clinical Trials on Alzheimer Disease
P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort
study (LCS)
Michael T. Ropacki, PhD , John Harrison, PhD, Joel Kramer, PsyD
, Christopher Randolph, PhD, Jeffrey Kaye, MD, Bruce Albala, PhD, Karen
Ritchie, PhD
OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory
guidance and 2018 NIA-AA research framework
Michael T. Ropacki, PhD , Suzanne Hendrix, PhD
http://www.ctad-alzheimer.com/files/files/CTA...t%20BD.pdf
In case you forgot who Dr. Ropacki, PhD is:
Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program - APRIL 16, 2018
https://www.amarantus.com/news/press-releases...ef-medical
P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort
study (LCS)
Michael T. Ropacki, PhD , John Harrison, PhD, Joel Kramer, PsyD
, Christopher Randolph, PhD, Jeffrey Kaye, MD, Bruce Albala, PhD, Karen
Ritchie, PhD
OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory
guidance and 2018 NIA-AA research framework
Michael T. Ropacki, PhD , Suzanne Hendrix, PhD
http://www.ctad-alzheimer.com/files/files/CTA...t%20BD.pdf
In case you forgot who Dr. Ropacki, PhD is:
Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program - APRIL 16, 2018
https://www.amarantus.com/news/press-releases...ef-medical
(5)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼